natgillin/translations-raw huggingface dataset:
Cirka 15,0 mm x 8,0 mm hvid, oval, bikonveks, filmovertrukket tablet med afskåret kant mærket med “MLR4” på den ene side og uden mærkning på den anden side.
Approx 15.0 mm x 8.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR4' on one side of the tablet and plain on the other side.
Cirka 18,8 mm x 10,0 mm hvid, oval, bikonveks, filmovertrukket tablet med afskåret kant mærket med “MLR3” på den ene side og uden mærkning på den anden side.
Approx 18.8 mm x 10.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR3' on one side of the tablet and plain on the other side.
Cirka 29 % af de patienter, der fik en dosis Darzalex på 16 mg/kg (31 ud af 106 patienter), udviste fuld eller delvis respons på behandlingen i den ene undersøgelse; i den anden undersøgelse var denne andel på 36 % (15 ud af 42 patienter).
Around 29% of the patients receiving Darzalex at a dose of 16 mg/kg (31 out of 106 patients) responded completely or partially to treatment in one study and 36% (15 out of 42 patients) in the second study.
Cirka 40 % af patienterne (kombineret APEX og FACT) havde et serumurinsyreniveau ved baseline på ≥ 595 µmol/l (10 mg/dl).
Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of ≥ 10 mg/dL.
Cirka 40-50 timer efter administration af PhotoBarr skal der afgives lys ved hjælp af en fiberoptik- diffusor ledt gennem den centrale kanal af en centreringsballon.
Approximately 40-50 hours after PhotoBarr administration, light should be delivered by a fibre optic diffuser passed through the central channel of a centring balloon.
Cirka 5-20 % af methotrexat og 1-5 % af 7-hydroxymethotrexat elimineres via galden.
5-20% of methotrexate and 1-5% of 7- hydroxymethotrexate are eliminated via the bile.
Cirka 6 % af patienterne i undersøgelserne udviklede længerevarende antistoffer mod natalizumab.
About 6% of the patients in the studies developed long-lasting antibodies against natalizumab.
Cirka 60 % af de patienter, der blev behandlet med cinacalcet, opnåede en reduktion på 30 % i iPTH-niveauet, og denne virkning var konsekvent for hele spektret af baseline-iPTH-niveauer.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Cirka 60 % af de patienter, der blev behandlet med cinacalcet, opnåede en reduktion på  30 % i iPTH-niveauet, og denne virkning var konsekvent for hele spektret af baselinie-iPTH-niveauer.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Cirka 60% af de patienter, der blev behandlet med cinacalcet, opnåede en reduktion på 30% i iPTH-niveauet, og denne virkning var konsekvent for hele spektret af baseline-iPTH-niveauer.
Approximately 60% of cinacalcet-treated patients achieved a ≥ 30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Cirka 8 % af patienterne havde en alvorlig bivirkning (common toxicity criteria, (CTC), grad 3 eller 4).
Approximately 8% of patients had a severe ADR (common toxicity criteria, (CTC) grade 3 or 4).
Cirka 80 % af patienterne udviklede neutraliserende antistoffer, som var i stand til at hindre elosulfase alfa i at binde sig til den kation-uafhængige mannose-6-phosphat-receptor.
Approximately 80% of patients developed neutralizing antibodies capable of inhibiting the elosulfase alfa from binding to the cation- independent mannose-6-phosphate receptor.
Cirka 80% af dosen blev genvundet i urinen og 15% i fæces.
Approximately 80% of the dose was recovered in the urine and 15% in the faeces.
Cirka 85 % af de patienter, der fik LEMTRADA, blev testet positive for anti-alemtuzumab-antistoffer i løbet af studiet, og 92 % af disse patienter blev også testet positive for antistoffer, der hæmmede LEMTRADA-binding in vitro.
Approximately 85% of patients receiving LEMTRADA tested positive for anti-alemtuzumab antibodies during the study, with 92% of these patients testing positive also for antibodies that inhibited LEMTRADA binding in vitro.
Cirka 90 % af spinosad består af spinosyner A og D. Af de 90 %, er forholdet af spinosyn A til A+D 0,85 når beregnet som spinosyn A/spinosyn A+D. Konsekvensen af dette tal i farmakokinetiske og andre studier angiver sammenlignelighed i absorption, metabolisme og eliminering af de to vigtigste spinosyner.
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Cirka 90% af spinosad består af spinosyner A og D. Af de 90%, er forholdet af spinosyn A til A+D 0,85 når beregnet som spinosyn A/spinosyn A+D. Konsekvensen af dette tal i farmakokinetiske og andre studier angiver sammenlignelighed i absorption, metabolisme og eliminering af de to vigtigste spinosyner.
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Cirka 92% af en dosis elimineres under beta- eliminationsfasen med en eliminationshalveringstid på 30 minutter.
Approximately 92 % of the dose is eliminated during ß-phase with a short elimination half-life of 30 minutes.
Cirka 92% af en dosis elimineres under beta- eliminationsfasen med en eliminationshalveringstid på 30 minutter.
Approximately 92% of the dose is eliminated during ß-phase with a short elimination half-life of 30 minutes.
Cirka 98 % af meloxicam er bundet til plasmaproteiner.
Approximately 98% of meloxicam is bound to plasma proteins.
Cirka halvdelen af de patienter, som tog Inovelon, havde mindre voldsomme anfald, sammenlignet med en tredjedel af de patienter, der tog placebo.
An improvement in the severity of seizures was reported for about half of the patients adding Inovelon, compared with a third of those adding placebo.
Cirka halvdelen af patienterne havde mindst 3 års forudgående behandling med Viramune 200 mg, før inkludering i studie 1100.1526.
Approximately half of the patients had at least 3 years of prior exposure to Viramune immediate-release prior to entering study 1100.1526.
Cirkulerende hydrochlorthiazid er bundet til serumproteiner (40– 70 %), hovedsagelig serumalbumin.
Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin.
Cirkulerende hydrochlorthiazid er bundet til serumproteiner (40–70 %), hovedsagelig serumalbumin.
Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin.
Cirkulerende IGF-1 spiller en vigtig rolle i dannelse og opretholdelse af knoglemasse.
Circulating IGF-1 plays an important role in the acquisition and maintenance of bone mass.
Cirkulerende koncentrationer af VEGF-bundet aflibercept øges med aflibercept- dosen indtil det meste tilgængelige VEGF er bundet.
Circulating concentrations of VEGF-bound aflibercept increase with the aflibercept dose until most available VEGF is bound.
Cirkulerende rotavirus- stammer
Circulating rotavirus strains
cirrose
107
cirrose
with cirrhosis
Cirrose status
Cirrhosis Status
Cirrosea
Cirrhosisa
Cirrosec
Cirrhosisc
Cirrosekohorte N = 60
Cirrhotic cohort N = 60
CIRS-G ≤ 10 (n=310)
CIRS-G ≤10 (n=310)
Cis Bio International, Nancy, Frankrig
Cis Bio International, Nancy, France
Cis Bio International, Nîmes, Frankrig
Cis Bio International, Nîmes, France
Cis Bio International, Paris, Frankrig
Cis Bio International, Paris, France
Cis Bio International, Pessac, Frankrig
Cis Bio International, Pessac, France
Cis Bio International, Rennes, Frankrig
Cis Bio International, Rennes, France
Cis+5-FU
Cis + 5-FU
Cisaprid
GI motility agent
Cisaprid (anvendes mod fordøjelsesbesvær og halsbrand)
Cisapride (used for indigestion and heartburn)
cisaprid (anvendes til behandling af maveproblemer) pimozid (anvendes til behandling af symptomer ved Tourettes sygdom)
cisapride (used to treat stomach problems) pimozide (used to treat symptoms of Tourette's disorder)
cisaprid (anvendes til behandling af maveproblemer) pimozid (anvendes til behandling af symptomer ved Tourettes syndrom og psykiske sygdomme)
cisapride (used to treat stomach problems) pimozide (used to treat symptoms of Tourette's and mental illness)
cisaprid (anvendes til behandling af maveproblemer) pimozid (anvendes til behandling af symptomer ved Tourettes syndrom)
cisapride (used to treat stomach problems) pimozide (used to treat symptoms of Tourette's disorder)
cisaprid (anvendes til lindring af visse maveproblemer)
cisapride (used to relieve certain stomach problems);
cisaprid (anvendes til lindring af visse maveproblemer)
cisapride (used to treat certain stomach problems);
cisaprid (anvendes til maveproblemer)
cisapride (used for stomach problems);
cisaprid (anvendt til at behandle maveproblemer).
cisapride (used to relieve certain stomach problems)
cisaprid (bruges mod visse maveproblemer);
cisapride (used to relieve certain stomach problems);
cisaprid (bruges til behandling af symptomer på halsbrand om natten); pimozid (bruges til behandling af symptomer på Tourettes sygdom, for eksempel udstøden af lyde og ukontrollerede, gentagne kropsbevægelser);
cisapride (used to treat symptoms of night time heartburn); pimozide (used to treat the symptoms of Tourette's syndrome e.g. vocal outbursts and uncontrolled, repeated movements of the body);
cisaprid (bruges til lindring af visse maveproblemer);
cisapride (used to relieve certain stomach problems);
cisaprid (brugt til lindring af visse maveproblemer);
cisapride (used to relieve certain stomach problems);
cisaprid (gastrointestinale motilitetsstimulerende midler)
cisapride (gastrointestinal motility agent)
cisaprid (gastrointestinale motilitetsstimulerende midler)
cisapride (gastrointestinal motility agents)
cisaprid (gastrointestinalt motilitetsfremmende middel)
cisapride (gastrointestinal motility agent)
Cisaprid (medicin mod maveproblemer)
Cisapride (used for stomach problems)
cisaprid (medicin mod maveproblemer)
cisapride (used to treat stomach problems)
cisaprid (mod fordøjelsesproblemer)
cisapride (digestive problems)
Cisaprid (mod halsbrand eller problemer med dit fordøjelsessystem)
Cisapride (for heart burn or problems with your digestive system)
cisaprid (mod halsbrand)
cisapride (used to treat heartburn)
cisaprid (mod halsbrand), pimozid (mod gentagne, ufrivillige bevægelser og verbale udbrud) og halofantrin og lumefantrin (mod malaria)
cisapride ( used to treat heart burn), pimozide (used to treat uncontrolled repeated movements of the body and verbal outbursts) and halofantrine and lumefantrine (used to treat malaria)
cisaprid (mod halsbrand), pimozid (mod gentagne, ufrivillige bevægelser og verbale udbrud) og halofantrin og lumefantrin (mod malaria)
cisapride (used to treat heart burn), pimozide (used to treat uncontrolled repeated movements of the body and verbal outbursts) and halofantrine and lumefantrine (used to treat malaria)
cisaprid (mod maveproblemer)
cisapride (used for stomach problems),
cisaprid (mod mavesyre-reflux fra mavesæk til spiserør) nogle typer vanddrivende medicin (diuretika), der kan medføre nedsat kaliumniveau i blodet, såsom furosemid, hydrochlorthiazid, indapamid (anvendt til at behandle ødemer og højt blodtryk)
Some types of diuretics which may cause decrease in blood potassium level, such as furosemide, hydrochlorothiazide, indapamide (used to treat oedema, high blood pressure).
Cisaprid (saquinavir/ritonavir)
e.g. dapsone, disopyramide, quinine, fentanyl, and alfentanyl
cisaprid (til behandling af fordøjelsesbesvær)
cisapride (used to relieve indigestion)
Cisaprid (til behandling af problemer med fordøjelsen)
cisapride (used for treating digestive problems),
cisaprid eller det syreneutraliserende middel magnesium-aluminium-hydroxid, der anvendes til behandling af halsbrand
cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn
cisaprid eller magnesium-aluminium-hydroxid, et syreneutraliserende middel, der anvendes til behandling af halsbrand
cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn
Cisaprid Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjet plasmakoncentration af cisaprid og er derfor kontraindiceret (se pkt 4.3).
Cisapride Ritonavir co-administration is likely to result in increased plasma concentrations of cisapride and is therefore contraindicated (see section 4.3).
cisaprid – anvendes til behandling af maveproblemer
cisapride – used to treat stomach problems
cisaprid – anvendes ved maveproblemer
cisapride - used for gut problems
cisaprid – medicin, der bruges til at behandle visse lidelser i fordøjelsessystemet
cisapride – a medicine used to treat certain digestive system problems
Cisaprid, droperidol, domperidon, bepridil, diphemanil, probucol, levomethadyl, metadon, vinca alkaloider, arseniktrioxid.
Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.
cisaprid, et lægemiddel, der anvendes til at lindre visse maveproblemer
cisapride, a medicine used to relieve certain stomach problems
Cisaprid, halofantrin, pimozid, quinidin, bepridil
Cisapride, halofantrine, pimozide, quinidine, bepridil
Cisaprid, til behandling af maveproblemer.
Cisapride, used to treat stomach problems.
Cisapride, droperidol, domperidone, bepridil, dephemanil, probucol, levomethadyl, methadone, vinca alkaloider, arsenisk trioxide.
Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.
Cisplatin (medicin mod forskellige typer kræft)
cisplatin (to treat various types of cancers);
cisplatin 50 mg/m2 d.
Cisplatin 50mg/m2 d.1 q21 d.
Cisplatin 50 mg/m2 på dag 1 hver 21. dag
Cisplatin 50 mg/m2 d.
Cisplatin gives efter topotecan som en intravenøs infusion på dag 1 i en dosis på 50 mg/m2/dag.
Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose.
Cisplatin produktinformation bør konsulteres for en komplet liste over bivirkninger associeret til brugen af cisplatin.
The prescribing information for cisplatin should be consulted for a full list of adverse events associated cisplatin use.
Cisplatin produktinformation bør konsulteres foren komplet liste over bivirkninger associeret til brugen af cisplatin.
The prescribing information for cisplatin should be consulted for a full list of adverse events associated cisplatin use.
cisplatin – 80 mg/m2 hver 3. uge i 6 serier på dag 1 i hver serie.
cisplatin - 80 mg/m2 every 3 weeks for 6 cycles on day 1 of each cycle.
Cisplatin/Gemcitabin
Cisplatin/Gemcitabine
Cisplatins produktinformation bør konsulteres for en komplet liste over bivirkninger associeret til brugen af cisplatin.
The prescribing information for cisplatin should be consulted for a full list of adverse events associated cisplatin use.
Cisplation og 5-fluoruracil
Cisplatin and 5-fluorouracil
citabin/teno-
tenofovir
citalopram (bruges til behandling af depressive episoder), omeprazol (bruges til behandling af mavesår)
citalopram (used in the treatment of depressive episodes), omeprazole (used in case of gastric ulcer)
Citalopram, imipramin eller clomipramin (anvendes til behandling af depression)
Citalopram, imipramine or clomipramine (used to treat depression)
Citrattoksicitet*
Citrate toxicity
Citronsyre
cholesterol
Citronsyre
Citric acid,
Citronsyre (E330) Natriumchlorid Vand til injektion
Citric acid (E330) Sodium chloride Water for injections
Citronsyre (E330) Renset vand
Citric acid (E330) Purified water
Citronsyre Honningaroma Vand, renset
Citric acid Honey aroma Water, purified
Citronsyre Honningduft Vand, renset
Citric acid Honey aroma Water, purified
Citronsyre Thiomersal
Citric acid, Thiomersal,
Citronsyre, monohydrat Sorbitol, flydende
Citric Acid Monohydrate Sorbitol Solution
Citronsyre, monohydrat Sorbitol, flydende
Colloidal silicon dioxide Citric acid monohydrate Sorbitol solution
Citronsyre, Thiomersal,
Citric acid, Thiomersal,
Citronsyre, vandfri
Citric acid anhydrous
Citronsyre, vandfri (E330) Natriumbenzoat (E211) Renset vand
Citric acid, anhydrous (E330) Sodium benzoate (E211) Purified water
Citronsyre, vandfri (til pH-justering) Natriumhydroxid (til pH-justering)
Citric acid anhydrous (to adjust the pH) Sodium hydroxide (to adjust the pH)
Citronsyre, vandfri Natriumcitrat
Anhydrous citric acid Sodium citrate
Citronsyremonohydrat (E330) Natriumcitrat (E331) Saccharose
Citric acid monohydrate (E330) Sodium citrate (E331)
Citronsyremonohydrat (E330) Trehalosedihydrat Lysinhydrochlorid
Citric acid monohydrate (E330) Trehalose dihydrate
Citronsyremonohydrat Natriumhydroxid
Citric acid monohydrate
Citronsyremonohydrat, natriumhydroxid, vand til injektionsvæsker.
Citric acid monohydrate, sodium hydroxide, water for injections.
Citronsyremonohydrat.
Citric acid monohydrate.
citrullinaemia type 1
citrullinaemia type 1;
Citywest Business Campus, Dublin 24
Citywest Business Campus, Dublin 24,
CK bør måles hyppigere (f.eks. hver 2.-3. dag i minimun de første to uger af behandlingen) hos patienter, som har øget risiko for at udvikle myopaty, f.eks. patienter med alle grader af nedsat nyrefunktion (kreatininclearance < 80 ml/min; se også pkt.
CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy.
CK-værdierne skal måles ugentligt i 2 måneder efter genoptaget administration af sonidegib og derefter månedligt.
CK levels should be measured weekly for
CKD i hæmodialyse
CKD on Haemodialysis
CL (dl/t/kg)
CL (dL/h/kg)
CL (l/t)
CL (L/h)
CL (l/t)
CL (L/hr)
CL (ml/time/kg)
CL (mL/hr/kg)
CL (µg /time/ml)
CL (ml/h/kg)
CL = clearance, MRT = mean residence time; Vss = fordelingsvolumen ved steady-state
CL = clearance; MRT = mean residence time; Vss = volume of distribution at steady-state
CL = clearance; Vd = distributionsvolumen; t½ = halveringstid Absorption:
CL = clearance; Vd = distribution volume; t½ = half life Absorption
CL, ml/minut/kg‡
CL, ml/minute/kg
Cl/F (l/t)
Cl/F (L/h)
CLa (ml/t/kg)
CLa (ml/h/kg)
cladribin /lamivudin
cladribine /lamivudine
cladribin /raltegravir
cladribine /raltegravir
Cladribin er en purinanalog (et stof, der har en kemisk struktur svarende til purin).
Cladribine is an ‘analogue’ of purine (a substance that has a similar chemical structure to purine).
cladribin til behandling af hårcelleleukæmi. rifampicin til behandling af tuberkulose (TB) og andre bakterieinfektioner.
cladribine, used to treat hairy cell leukaemia rifampicin, to treat tuberculosis (TB) and other bacterial infections
Cladribin/lamivudin
Cladribine/Lamivudine
Cladribine elimineres hovedsageligt af nyrerne.
Cladribine is eliminated mainly by the kidneys.
Cladribine er en purinnukleosidanalog, der virker som en antimetabolit.
Cladribine is a purine nucleoside analogue acting as an antimetabolite.
Cladribine er et antineoplastisk og immunsuppressivt stof, der kan inducere betydelige uønskede, toksiske bivirkninger, som fx myelo- og immunsuppression, langvarig lymfocytopeni og opportunistiske infektioner.
Cladribine is an antineoplastic and immunosuppressive substance that can induce considerable toxic adverse reactions, such as myelo- and immunosuppression, long-lasting lymphocytopenia, and opportunistic infections.
Cladribine er et cytostatisk middel.
Cladribine is a cytostatic agent.
Cladribine er et cytotoksisk lægemiddel, som er mutagen for dyrkede pattedyrceller.
Cladribine is a cytotoxic medicinal product, which is mutagenic to cultured mammalian cells.
Cladribine er et pro-drug, som optages hurtigt i celler efter parenteral indgivelse, og det bliver fosforyleret intracellulært til det aktive nukleotid 2-klorodeoxyadenosin-5'-trifosfat (CdATP) ved deoxycytidinkinase (dCK).
Cladribine is a prodrug which is taken up rapidly in cells after parenteral administration, and is phosphorylated intracellularly to the active nucleotide 2-chlorodeoxyadenosine-5'-triphosphate (CdATP) by deoxycytidine kinase (dCK).
Cladribine er kontraindiceret under graviditet.
Cladribine is contraindicated in pregnancy.
Cladribine er moderat akut toksisk for mus, med en LD50 på 150 mg/kg ved intraperitoneal indgivelse.
Cladribine is moderately acutely toxic to mice, with an LD50 of 150 mg/kg by intraperitoneal administration.
Cladribine er teratogen hos mus (ved doser på 1,5-3,0 mg/kg/dag, givet på gestationsdag 6-15).
Cladribine is teratogenic in mice (at doses of 1.5-3.0 mg/kg/day, given on gestation days 6-15).
Cladribine forårsager sandsynligvis ikke alopecia (skaldethed); mild og kortvarig alopecia i et par dage blev observeret hos 4/523 patienter under behandling, men kunne ikke klart forbindes med cladribine.
Cladribine is unlikely to cause alopecia; mild and transient alopecia for a few days was observed in 4/523 patients during the treatment, but could not clearly be associated with cladribine.
Cladribine inducerer en alvorlig og forlænget reduktion af CD4+ og CD8+ T-lymfocytter.
Cladribine induces a severe and prolonged reduction of CD4+ and CD8+ T-lymphocytes.
Cladribine inkorporeres i DNA-strenge og hæmmer DNA-syntese og -vedligeholdelse.
Cladribine is incorporated into DNA strands and inhibits DNA synthesis and repair.
Cladribine medfører alvorlige medfødte misdannelser, når det anvendes under graviditeten.
Cladribine causes serious birth defects when administered during pregnancy.
Cladribine viser fuldstændig biotilgængelighed efter parenteral indgivelse; middelområdet under plasmakoncentrationen kontra tidskurve (AUC) i plasma er sammenlignelig efter kontinuerlig eller intermitterende intravenøs infusion af 2 timers varighed og efter subkutan injektion.
Cladribine shows complete bioavailability after parenteral administration; the mean area under the plasma concentration versus time curve (AUC) is comparable after continuous or intermittent 2-hour intravenous infusion and after subcutaneous injection.
Cladribines effekt på fertiliteten er ikke blevet undersøgt hos dyr.
The effects of cladribine on fertility have not been studied in animals.
Clarithromycin
or posaconazole.
clarithromycin (antibiotika) nefazodon (lægemiddel mod depresion)
clarithromycin (antibiotic) nefazodone (anti-depressor)
clarithromycin (antibiotikum mod bakterieinfektioner) indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, atazanavir (mod HIV-infektion) telaprevir (mod leversygdommen hepatitis C)
clarithromycin (an antibiotic medicine used to treat bacterial infections) indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, atazanavir (medicines against HIV infection) telaprevir (a medicine used to treat a liver disease called hepatitis C)
clarithromycin (fx azithromycin)
Raltegravir:
clarithromycin (mod infektioner der skyldes bakterier)
clarithromycin (used to treat bacterial infections)
Clarithromycin (saquinavir/ritonavir)
(e.g. amitriptyline,
Clarithromycin / lamivudin
Clarithromycin/Lamivudine
Clarithromycin 500 mg 2
Clarithromycin 500 mg twice
Clarithromycin 500 mg 2 gange dagligt
Clarithromycin
Clarithromycin 500 mg to gange
Clarithromycin 500 mg twice daily
Clarithromycin 500 mg to gange dagligt
Clarithromycin 500 mg twice daily
Clarithromycin 500 mg x 2
Clarithromycin 500 mg BID
Clarithromycin 500 mg x 2
Clarithromycin 500 mg twice daily
clarithromycin AUC ↑ 57 % clarithromycin Cmin ↑ 174 % clarithromycin Cmax ↑ 26 %
clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26
Clarithromycin Cmax ↓ 0,77 (0,69-
Clarithromycin Cmax ↓ 0.77 (0.69
Clarithromycin Cmin ↓ 0,44 (0,30-
Clarithromycin Cmin ↓ 0.44 (0.30
Clarithromycin Cmin  0,44 (0,30-0,64)
Clarithromycin Cmin  0.44 (0.30
clarithromycin eller
or voriconazole.
clarithromycin eller telithromycin - antibiotika ritonavir, indinavir eller saquinavir – til behandling af hiv
clarithromycin or telithromycin - antibiotics ritonavir, indinavir or saquinavir – to treat HIV
clarithromycin eller telithromycin.
clarithromycin or telithromycin.